EP0461546A2 — Antiherpes peptide derivatives having a 1,4-dioxo-C4 N-terminus
Assigned to Bio Mega Boehringer Ingelheim Research Inc · Expires 1991-12-18 · 34y expired
What this patent protects
Disclosed herein are peptide derivatives of the formula R¹NH-CO-Q-C(O)-NR²-CH[CH₂C(O)-Y]-C(O)-NH-CH[CR³(R⁴)-COOH]-C(W)-NH-CHR⁵-Z wherein R¹ is an optionally substituted alkyl or optionally substituted phenylalkyl, R² is hydrogen or alkyl, R³ and R⁴ each independently is hydrogen …
USPTO Abstract
Disclosed herein are peptide derivatives of the formula R¹NH-CO-Q-C(O)-NR²-CH[CH₂C(O)-Y]-C(O)-NH-CH[CR³(R⁴)-COOH]-C(W)-NH-CHR⁵-Z wherein R¹ is an optionally substituted alkyl or optionally substituted phenylalkyl, R² is hydrogen or alkyl, R³ and R⁴ each independently is hydrogen or alkyl, or R³ and R⁴ are joined to form a cycloalkyl, R⁵ is alkyl, cycloalkyl or (cycloalkyl)alkyl, Q is a divalent radical, for example, -CH₂CH₂-, -CH=CH- or 1,2-cyclohexanediyl, which serves as a two carbon spacer, W is oxo or thioxo, Y is, for example, an alkoxy or a monosubstituted or disubstituted amino, and Z is a terminal unit, for example, hydrogen, COOH or CH₂OH. The derivatives are useful for treating herpes infections.
Drugs covered by this patent
- Wayrilz (RILZABRUTINIB) · Genzyme Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.